logo
  |   Important Safety Information   |   AstraZeneca Web Sites
logo
  • >Home
  • >Why PULMICORT RESPULES
    • >Reduces Asthma Symptoms
    • >Reduces Rescue ?2-Agonist Use
    • >How PULMICORT RESPULES Works
  • >Using a Nebulizer
    • >Nebulizer Basics
    • >Jet Nebulizers vs Other Devices
    • >Locate a Nebulizer
  • >Dosing and Safety
    • >Flexible Dosing Options
    • >Well-Established Safety Profile
  • >Educating Your Patients
    • >AsthmaKidCare™ Pro
    • >Using the Asthma Action Plan
    • >Seasonal Asthma Triggers
    • >Talking to Parents About ICSs
    • >Patient & Parent Support
    • >Asthma Guidelines and Resources
      • >Asthma Guidelines
      • >Healthcare Professional Resources

    Page Not Found

    Enlarge Text: A A A
    Print: print
    Resource Not Found Page Resource Not Found Page Content

    Indication

    PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children ages 12 months to 8 years.

    PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.

    Important Safety Information

    Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown.

    PULMICORT RESPULES, like other inhaled corticosteroids, may impact the hypothalamic-pituitary-adrenal axis, especially in susceptible individuals, in young children, and in patients given high doses for prolonged periods.

    Particular care is needed for patients who are transferred from systemically active corticosteroids to less systemically available corticosteroids, because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids (see WARNINGS in full Prescribing Information).

    Patients taking immunosuppressant doses of corticosteroids should avoid exposure to infections such as chicken pox and measles.

    Common adverse events reported in clinical trials, regardless of relationship to treatment, included respiratory infection, rhinitis, coughing, otitis media, viral infection, gastroenteritis, ear infection, oral thrush/candidiasis, and epistaxis.

    Please see accompanying full Prescribing Information (PDF).

    flag 

      This product information is intended for US healthcare professionals only.

    PULMICORT RESPULES is a registered trademark and AsthmaKidCare is a trademark of the AstraZeneca group of companies.

    ©2009 AstraZeneca LP. All rights reserved. 292875 12/09

    Privacy Statement | Legal Terms and Conditions | US Corporate Site

    Site Map  |   References  |   Contact Us